Journal: Cancer cell

Article Title: Taxanes trigger cancer cell killing in vivo by inducing non-canonical T cell cytotoxicity.

doi: 10.1016/j.ccell.2023.05.009

Figure Lengend Snippet: Figure 5. Pre-clinical assessment of the therapeutic benefits of T cells pre-treated with docetaxel (A) Representative images and quantification of cleaved-caspase 3 (CC3) immunofluorescent staining in MMTV-PyMT organoids expressing OVA and co- cultured with T cells isolated from the spleen of OT I mice upon pre-treatment with a vehicle control or docetaxel. n = 3 biological repeats, scale bar = 100 mm. Data are presented as mean ± SEM, p values were determined using unpaired, nonparametric t-test with a Mann-Whitney U correction in GraphPad Prism. (B) Schematic representation of experiment design. (C and D) Tumor growth in mice bearing KB1P tumors (C) or MMTV-PyMT tumors (D) and transplanted with CD4+ T cells pre-treated in vitro with a vehicle control or with docetaxel. For Figure 5C, the p value was determined in R using a linear mixed-effects model, for Figure 5D, due to the lower number of animals, the p value was determined in Prism GraphPad using a mixed-effects analysis with a Geisser-Greenhouse correction. (E and F) Kaplan-Meier analysis of survival from time of T cell transfer in mice bearing KB1P tumors (E) or MMTV-PyMT tumors (F) transplanted with CD4+ T cells pre-treated in vitro with a vehicle control or with docetaxel. For E and F, p = values were determined using a log rank Mantel-Cox test in GraphPad Prism. See also Figure S5, Tables S1, and S2.

Article Snippet: Vehicle for cyclophosphamide: saline; vehicle for doxorubicin: saline; vehicle for docetaxel: acetonitrile containing 0.1% acetic acid. d IgG treatment: on day 1, day 3 and day 5 prior to treatment with vehicle control or with chemotherapy, treatment with 400 mg (day 1), or 200 mg (day 3 and day 5) per mouse with InVivoMAb rat IgG2b isotype control (BioXCell, clone LTF-2, Cat. No. BE0090). d aCD4 treatment: on day 1, day 3 and day 5 prior to treatment with vehicle control or with chemotherapy, treatment with 400 mg (day 1), or 200 mg (day 3 and day 5) per mouse with InVivoMAb anti-mouse CD4 (BioXCell, clone GK1.5, Cat. No. BE003-1). d aCD8 treatment: on day 1, day 3 and day 5 prior to treatment with vehicle control or with chemotherapy, treatment with 400 mg (day 1), or 200 mg (day 3 and day 5) permouse with InVivoMAb anti-mouse CD8 (BioXCell, clone YTS 169.4, Cat. No. BP0117).

Techniques: Staining, Expressing, Cell Culture, Isolation, Control, MANN-WHITNEY, In Vitro

Journal: Antibodies

Article Title: Evaluating the Therapeutic Efficacy of an Anti-BAFF Receptor Antibody Using a Rheumatoid Arthritis Mouse Model

doi: 10.3390/antib14040090

Figure Lengend Snippet: Antibody-mediated dose-dependent inhibition of B220+/CD21+CD23+ B-cell proliferation analyzed by flow cytometry. ( A ) CD21+ CD23+ cells, ( B ) B cells. Splenocytes from C57BL/6 mice (1 × 10 6 cells/mL) were treated with or without the following: BAFF [7 ng/mL]. mIgG2a isotype control mAb (clone-c1.18.4), mIgG1 isotype control mAb (clone-MOPC-21), V3-1 mIgG2a mAb, V3-46s mIgG2a mAb, and V3-46s mIgG1 mAb were added in a dose-dependent manner, as indicated, with 3-fold dilutions starting at 3 µg/mL, and cultured for 72 h at 37 °C. Cells were then stained for B220, CD21, and CD23, and visualized on a CytoflexL4.

Article Snippet: Cells were then stained for CD45 (Biolegend, catalog BLG-103108), B220 (Miltenyi, catalog 130-110-846), CD21/CD35 (Miltenyi, catalog 130-111-732), CD23 (Miltenyi, catalog 130-118-761), and DAPI (Sigma, catalog D9542), and were visualized on a CytoflexL4 (Beckman Coulter) flow cytometer.

Techniques: Inhibition, Flow Cytometry, Control, Cell Culture, Staining

Journal: BMC Molecular and Cell Biology

Article Title: Transcriptome and proteome profiling reveal complementary scavenger and immune features of rat liver sinusoidal endothelial cells and liver macrophages

doi: 10.1186/s12860-020-00331-9

Figure Lengend Snippet: Antibodies used in the study

Article Snippet: CD11b/c Biotin (OX-42) , CD11b/c, CR3 , Cedarlane , CL042B , 2 μg/ml.

Techniques: Concentration Assay, Flow Cytometry, Control, Staining, FACS